Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
The Lancet Investigational Trial Context: MASLD/Liver Fat (Nature Medicine, 2024) A Phase 2a investigational trial published in Nature Medicine found that the triple GIP/GLP-1/glucagon receptor agonist resulted in substantial reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease (MASLD)
PMid:21813919
And this has happened with many other molecules over the years," he noted
PMID 41223250
JAMA Netw Open 2025;8:e2457349.ArticlePubMedPMC 116
US$ 27.69
US$ 27.23
US$ 29.49
US$ 24.46
US$ 23.43
US$ 29.60
US$ 27.33
US$ 20.24
US$ 20.86
